Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

What Does Good Look Like?

March 20th 2014

When I first entered practice in 1990, I was fortunate to have senior partners and colleagues who offered sage advice, much of it based on retrospective analysis of their own successes and failures over time.

Conclusion: Optimizing the Treatment of RCC

March 19th 2014

RCC Journal Highlights and Implications for Clinical Practice

March 19th 2014

Novel Therapies in Renal Cell Carcinoma

March 19th 2014

Evolving Role of Genomic Testing in RCC

March 19th 2014

Case Study: Utilizing Multiple Therapies in mRCC

March 19th 2014

Drug Holidays in Renal Cell Carcinoma

March 19th 2014

Case Study: Observation in Metastatic RCC

March 19th 2014

Case Study: Treating Progressive Renal Cell Carcinoma

March 19th 2014

Second-Line Angiogenesis Inhibition in mRCC

March 19th 2014

Second-Line Treatment of Metastatic Renal Cell Carcinoma

March 19th 2014

Optimizing the Upfront Treatment of mRCC

March 19th 2014

Cytoreductive Nephrectomy in Untreated Metastatic RCC

March 19th 2014

Frontline Treatment of Poor-Risk mRCC

March 19th 2014

Treatment of Metastatic Non-Clear Cell RCC

March 19th 2014

Introduction: Multidisciplinary Frontline Treatment of mRCC

March 19th 2014

Dr. Charles Ryan on Prescribing Preferences

March 13th 2014

Charles Ryan, MD, discusses community oncologist prescribing preferences for patients with prostate cancer or renal cell carcinoma.

Exceptional Responder Provides Treatment Clues in Bladder Cancer

March 13th 2014

An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib.

Dr. Plimack on an mTOR/HDAC Inhibitor Combination in RCC

March 11th 2014

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial that looked at overcoming mTOR resistance with an HDAC inhibitor in renal cell carcinoma (RCC).

Dr. Figlin on Intermediate Prognosis Patients With mRCC

March 5th 2014

Robert Figlin, MD, FACP, discusses an analysis of the heterogeneity of intermediate prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.